Targeted drug shows promise as Post-Transplant maintenance for rare blood cancers
NCT ID NCT03515512
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 28 times
Summary
This study tested the drug enasidenib as a maintenance therapy for people with IDH2-mutant acute myeloid leukemia or chronic myelomonocytic leukemia after a stem cell transplant. The goal was to find the safest dose and see how well patients tolerated it. Twenty-three participants were enrolled, and researchers monitored side effects and dose-limiting toxicities. The study was completed and provides early safety data for this approach.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Johns Hopkins Cancer Center
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.